Skip to main content
Top
Published in: Breast Cancer Research 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: Ubiquitin-conjugating enzyme complex Uev1A-Ubc13 promotes breast cancer metastasis through nuclear factor-кB mediated matrix metalloproteinase-1 gene regulation

Authors: Zhaojia Wu, Siqi Shen, Zhiling Zhang, Weiwei Zhang, Wei Xiao

Published in: Breast Cancer Research | Issue 1/2017

Login to get access

Excerpt

After the publication of this work [1] an error was noticed in Fig. 2d, in which an image from UEV1C transfected cells without Dox treatment (Dox-) was mistakenly presented as MMS2 transfected Dox- cell image. The corrected Fig. 2 that contains a replacement image for MMS2 transfected Dox- cells in Fig. 2d is presented. As UEV1C and MMS2 transfections have indistinguishable effects on cell invasion (Fig. 2e), the correction does not affect our conclusions. Nevertheless, we apologize for this error.
Literature
1.
go back to reference Wu Z, Shen S, Zhang Z, Zhang W, Xiao W. Ubiquitin-conjugating enzyme complex Uev1A-Ubc13 promotes breast cancer metastasis through nuclear factor-small ka, CyrillicB mediated matrix metalloproteinase-1 gene regulation. Breast Cancer Res. 2014;16:R75.CrossRefPubMedPubMedCentral Wu Z, Shen S, Zhang Z, Zhang W, Xiao W. Ubiquitin-conjugating enzyme complex Uev1A-Ubc13 promotes breast cancer metastasis through nuclear factor-small ka, CyrillicB mediated matrix metalloproteinase-1 gene regulation. Breast Cancer Res. 2014;16:R75.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: Ubiquitin-conjugating enzyme complex Uev1A-Ubc13 promotes breast cancer metastasis through nuclear factor-кB mediated matrix metalloproteinase-1 gene regulation
Authors
Zhaojia Wu
Siqi Shen
Zhiling Zhang
Weiwei Zhang
Wei Xiao
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2017
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-017-0833-6

Other articles of this Issue 1/2017

Breast Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine